Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.31
-2.6%
$5.57
$3.96
$9.85
$2.34B0.412.54 million shs902,877 shs
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$15.19
$8.13
$19.08
$24.33M0.4122,095 shs237,144 shs
Tervita Co. stock logo
TEV
Tervita
C$0.00
C$1.69
C$6.46
C$672.00MN/A79,738 shs15,893 shs
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$0.62
+1.6%
$0.46
$0.35
$2.15
$625.34M1.8231.21 million shs28.80 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
+0.68%-2.41%+13.14%+26.54%-14.90%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00%0.00%0.00%0.00%+30.01%
Tervita Co. stock logo
TEV
Tervita
0.00%0.00%0.00%0.00%0.00%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
+1.43%-4.05%+59.11%+35.84%-67.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
3.7238 of 5 stars
1.94.00.04.01.83.30.6
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.2142 of 5 stars
0.00.00.04.20.00.80.0
Tervita Co. stock logo
TEV
Tervita
N/AN/AN/AN/AN/AN/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
1.8657 of 5 stars
3.11.00.00.03.10.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1.83
Reduce$7.3015.69% Upside
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00
N/AN/AN/A
Tervita Co. stock logo
TEV
Tervita
0.00
N/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2.25
Hold$1.92208.49% Upside

Current Analyst Ratings Breakdown

Latest TLRY, BHC, CARA, and TEV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$9.63B0.24$7.60 per share0.83($0.89) per share-7.09
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$7.14M0.00N/AN/A$12.58 per share0.00
Tervita Co. stock logo
TEV
Tervita
C$1.36B0.00N/A29.62C$1.58 per share0.00
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$788.94M0.79N/AN/A$4.14 per share0.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-$46M-$0.11N/A1.35N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/A
Tervita Co. stock logo
TEV
Tervita
N/A-C$0.01N/AN/AN/AN/AN/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$244.98M-$1.05N/AN/AN/A-113.85%-7.40%-6.02%7/28/2025 (Estimated)

Latest TLRY, BHC, CARA, and TEV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$0.9320N/AN/AN/A$2.47 billionN/A
7/28/2025Q4 2025
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$0.03N/AN/AN/A$250.41 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/AN/AN/AN/AN/A
Tervita Co. stock logo
TEV
Tervita
N/AN/AN/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/A
1.35
0.97
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/A
4.77
4.71
Tervita Co. stock logo
TEV
Tervita
440.44
1.00
0.86
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.12
2.62
1.61

Institutional Ownership

CompanyInstitutional Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
44.66%
Tervita Co. stock logo
TEV
Tervita
N/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
9.35%

Insider Ownership

CompanyInsider Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
8.05%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
3.10%
Tervita Co. stock logo
TEV
Tervita
N/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,700370.08 million340.29 millionOptionable
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
804.57 million4.43 millionOptionable
Tervita Co. stock logo
TEV
Tervita
36,800115.66 millionN/ANot Optionable
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2,6501.01 billion1.00 billionOptionable

Recent News About These Companies

Tilray (TLRY) Stock Is Up, What You Need To Know
Tilray Brands (NASDAQ:TLRY) Shares Up 4% - What's Next?
Tilray Brands (NasdaqGS:TLRY) Soars 44% In Last Month
Cannabis Stocks To Follow Today - July 13th
Promising Cannabis Stocks To Follow Now - July 12th
Top Cannabis Stocks To Watch Today - July 11th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$6.31 -0.17 (-2.62%)
Closing price 03:59 PM Eastern
Extended Trading
$6.32 +0.01 (+0.08%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Cara Therapeutics stock logo

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Tervita stock logo

Tervita TSE:TEV

Tervita Corporation operates as an environmentally focused waste service provider in Canada and the United States. It operates through two segments, Energy Services and Industrial Services. The Energy Services segment treats, recovers, and disposes fluids; provides oil terminalling and energy marketing services; processes and disposes solid materials; disposes oilfield-generated waste; offers onsite services using centrifugation or other processes for heavy oil producers involved in mining and in situ production; and purchases and sells oil volumes with treatment, recovery, terminalling, and disposal services. The Industrial Services segment provides site remediation, facility decommissioning, water treatment, sludge and slurry management, bio-remediation and technologies, technical, environmental liability management, emergency response, and rail services, as well as hazardous and non-hazardous waste management, and disposal services. This segment also offers recycling services that include purchase and processing of ferrous and non-ferrous metals recovered from demolition sites and other locations. As of December 31, 2020, the company operated 103 active waste processing, disposal, and industrial facilities, including 44 treatment, recovery, and disposal facilities; eight stand-alone disposal wells; three cavern disposal facilities; eight onsite facilities; 22 engineered landfills; three transfer stations; one naturally occurring radioactive material facility; nine bioremediation facilities; and five metals recycling facilities. It serves oil and gas industry, and industrial and natural resource sectors. The company was formerly known as CCS Corporation and changed its name to Tervita Corporation in March 2012. Tervita Corporation was founded in 1979 and is headquartered in Calgary, Canada.

Tilray Brands stock logo

Tilray Brands NASDAQ:TLRY

$0.62 +0.01 (+1.64%)
Closing price 04:00 PM Eastern
Extended Trading
$0.62 0.00 (-0.05%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.